La vendita allo scoperto per Ovintiv dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Ovintiv. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Ovintiv (NYSE:OVV) Azioni, Report sulle vendite allo scoperto

Ovintiv

Ovintiv is a North American oil and natural gas exploration and production company. It focuses on the exploration and development of oil, NGLs, and natural gas reserves. The company has three segments: USA Operations, Canadian Operations, and Market Optimization.

Ovintiv Inc

Barclays analyst Michael Leithead maintains Chemours (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CC#NYSE">CC</a>) with a Equal-Weight and raises the price target from $21 to $23.

News

Price Target

Analyst Ratings

Barclays Maintains Equal-Weight on Chemours, Raises Price Target to $23

<a href="https://www.benzinga.com/topic/2024-election">Election Day has arrived</a>, and we could all probably use a deep breath. Take a moment if you need it.
Now, onto the cannabis front where voters in Nebraska, North Dakota, South Dakota and Florida <a href="https://www.benzinga.com/markets/cannabis/24/10/41387752/winding-road-to-cannabis-legalization-ahead-for-4-states-set-to-vote-in-2024-what-do-the-polls-s">will decide on ballot initiatives</a> to legalize marijuana for recreational or medical use. If approved, these states will join the 38 others that have embraced some form of cannabis legalization and join the rapidly changing landscape of <a href="https://www.benzinga.com/topic/cannabis-reform">marijuana policy</a> in the U.S.
Here's what&#8217;s changed in the landscape…some might even say drastically.
<h3 class="wp-block-heading">One Of Our Favorites: Adult Weed Consumption Rises As Teen Use Falls</h3>
Concerns over a spike in youth cannabis consumption following early legalization efforts, beginning with Colorado and Washington in 2012, have proven unfounded. Contrary to fears, marijuana use among teens has declined, or maybe never really took off.
From 2011 to 2021, the <a href="https://www.benzinga.com/topic/cannabis-reform">percentage of adolescents reporting marijuana use</a> dropped from 23% to under 16%.
"The ‘sky's going to fall' scenario was that all of the kids were just going to have access to all of the cannabis and it was going to be a terrible, terrible thing," said Ryan Vandrey, professor of psychiatry and behavioral sciences at Johns Hopkins Medicine who studies cannabis.
"It just goes to show that teenagers will do exactly the opposite of what you think they're going to do at all times," Vandrey <a href="https://www.nytimes.com/2024/11/04/well/weed-cannabis-america.html">told</a> The New York Times, confirming what every parent who has or is raising a teenager already knows.
Adult cannabis consumption, meanwhile, <a href="https://www.benzinga.com/markets/cannabis/24/08/40652731/cannabis-and-hallucinogen-consumption-hit-all-time-highs-in-2023-while-tobacco-and-alcohol-decli">has reached historic highs</a>, with 42% of individuals aged 19-30 and 29% of those aged 35-50 reporting use in the past year.
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/10/41609840/sharp-drop-in-teen-marijuana-use-legalization-and-demographics-examined">Sharp Drop In Teen Marijuana Use: Legalization And Demographics Examined</a>
<h3 class="wp-block-heading">Cannabis Use Surpasses Alcohol</h3>
Yeah, you read that right. Recent studies have show that more Americans are now consuming <a href="https://www.benzinga.com/markets/cannabis/24/05/38976556/daily-cannabis-consumption-outpaces-daily-alcohol-use-in-the-us-for-the-first-time-new-study-sho">weed daily rather than alcohol</a>. Nearly 18 million people report daily or near-daily marijuana use, outpacing the 15 million who drink with similar frequency. 
<h3 class="wp-block-heading">Seniors Jump On The Weed Wagon Because…Why Not?</h3>
The country&#8217;s 73 million baby boomers are among the&nbsp;<a href="https://www.benzinga.com/markets/cannabis/23/08/33583433/baby-boomers-turning-to-weed-en-masse-say-it-improves-memory-and-mood-doctors-agree-cnn-series-e" target="_blank" rel="noreferrer noopener">fastest-growing demographic</a><a href="https://www.benzinga.com/markets/cannabis/24/01/36458087/senior-cannabis-consumers-balancing-act-relief-for-numerous-conditions-comes-with-warnings-but-w" target="_blank" rel="noreferrer noopener">&nbsp;</a>of&nbsp;cannabis users in the U.S. and around the world. In the past 8 years, senior cannabis consumption has tripled. Seniors also happen to&nbsp;possess&nbsp;half of the nation's&nbsp;$140 trillion&nbsp;in wealth, so they&#8217;re helping the economy even after they&#8217;ve retired.
<h3 class="wp-block-heading">Closing That Gender Gap </h3>
Cannabis use has long been more prevalent among men than women, but that disparity is shrinking. In 2023, young women (ages 19-30) <a href="https://www.benzinga.com/markets/cannabis/24/08/40652731/cannabis-and-hallucinogen-consumption-hit-all-time-highs-in-2023-while-tobacco-and-alcohol-decli">reported higher rates of cannabis use</a> than their male counterparts. Teenage girls also now report higher marijuana use than boys, marking a shift in gender patterns of cannabis consumption.
Now Read: 
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/11/41726320/hemp-donations-fuel-desantis-and-florida-gops-charge-against-weed-legalization-new-findings">Hemp Donations Fuel DeSantis And Florida GOP&#8217;s Charge Against Weed Legalization, New Findings</a></li>
</ul>
Photo: Shutterstock

Cannabis

Government

Politics

Legal

Election Day 2024: Will Florida, Nebraska, North And South Dakota Join The Marijuana Revolution?

Barclays analyst Tom O'Malley maintains Astera Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALAB#NASDAQ">ALAB</a>) with a Overweight and raises the price target from $70 to $87.

ALAB

Barclays Maintains Overweight on Astera Labs, Raises Price Target to $87

Barclays analyst Julian Mitchell maintains APi Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APG#NYSE">APG</a>) with a Overweight and raises the price target from $43 to $44.

Barclays Maintains Overweight on APi Gr, Raises Price Target to $44

KITT

Nauticus Robotics Secures Agreement To Convert $33M Debt Into Equity Via Preferred Stock Exchange, Aiming To Deleverage Balance Sheet And Address Nasdaq Compliance

On CNBC's &#8220;Mad Money Lightning Round,&#8221; Jim Cramer said Ceva (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CEVA#NYSE">CEVA</a>) is &#8220;way too high, and I think you <a href="https://www.benzinga.com/quote/CEVA">should take something off the table.&#8221;</a>
Ceva will announce results for the third quarter on Nov. 7, 2024, before the opening bell.
&#8220;I love space stuff, and that's why I keep recommending Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>),&#8221; Cramer said when asked about Intuitive Machines, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUNR#NASDAQ">LUNR</a>). If there's going to be something in space, it is going to be done by Elon Musk."
Intuitive Machines will release its financial results for the third quarter on Thursday, Nov. 14, before the market opens.
When asked about Ford Motor Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>), &#8220;I want so badly for the company to do well, but I can't recommend the stock.&#8221;
The company is reportedly set to pause production of its F-150 Lightning from mid-November until the year&#8217;s end, citing weaker-than-anticipated demand for the electric pickup, Automotive News reported.
&#8220;They are in the oil service business, and oil is not a growth commodity. So, I'm going to say you can't own the stock here, as much as I really like them,&#8221; the &#8220;Mad Money&#8221; host said when asked about SLB (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLB#NYSE">SLB</a>).
The company, last week, disclosed that its OneSubsea joint venture won a contract from BP p.l.c. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BP#NYSE">BP</a>) for a subsea boosting system as part of the greenfield development of the Kaskida project in the deepwater U.S.
Cramer recommended taking something off the table, when asked about Vistra Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VST#NYSE">VST</a>).
Vistra will replace The AES Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AES#NYSE">AES</a>) in the Dow Jones Utility Average, effective prior to the open of trading on Friday, Nov. 8.
Price Action:
<ul>
<li>CEVA shares fell 0.2% to settle at $23.64 on Monday.</li>
<li>Intuitive Machines shares fell 6.5% to close at $7.58 on Monday.</li>
<li>Ford shares gained 1.4% to settle at $10.36 during the session.</li>
<li>SLB gained 1.4% to settle at $40.32 on Monday.</li>
<li>Vistra shares fell 3.2% to close at $115.74.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/24/11/41713185/top-4-tech-and-telecom-stocks-that-may-collapse-this-month">Top 4 Tech And Telecom Stocks That May Collapse This Month</a></li>
</ul>

Long Ideas

Markets

Media

CEVA

LUNR

TSLA

Jim Cramer Says He Can't Recommend This Major Automaker, Ceva Is 'Way Too High'

WIIM

DuPont shares are trading higher after the company reported better-than-expected Q3 EPS and raised its FY24 adjusted EPS guidance.

APLS

Apellis Pharmaceuticals shares are trading lower after the company reported worse-than-expected Q3 financial results.

Barclays analyst Matt Miksic maintains Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) with a Overweight and raises the price target from $143 to $149.

Barclays Maintains Overweight on Abbott Laboratories, Raises Price Target to $149

Pfizer's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) short percent of float has risen 5.04% since its last report. The company recently reported that it has 70.94 million shares sold short, which is 1.25% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.22 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Pfizer Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730814324_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Pfizer has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Pfizer's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Pfizer's peer group average for short interest as a percentage of float is 4.87%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

Peering Into Pfizer's Recent Short Interest

KKR's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KKR#NYSE">KKR</a>) short percent of float has fallen 13.57% since its last report. The company recently reported that it has 11.63 million shares sold short, which is 1.72% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.97 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>KKR Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730814319_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for KKR has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing KKR's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, KKR's peer group average for short interest as a percentage of float is 3.67%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Looking Into KKR's Recent Short Interest

PDD Holdings's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PDD#NYSE">PDD</a>) short percent of float has fallen 7.83% since its last report. The company recently reported that it has 32.98 million shares sold short, which is 4.0% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.69 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>PDD Holdings Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730814314_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for PDD Holdings has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing PDD Holdings's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, PDD Holdings's peer group average for short interest as a percentage of float is 9.86%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Citigourp Global Markets 2% Protected Notes Linked To The Djia

Looking Into PDD Holdings's Recent Short Interest

Barclays analyst Steven Valiquette maintains Owens &amp; Minor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OMI#NYSE">OMI</a>) with a Equal-Weight and lowers the price target from $18 to $14.

Barclays Maintains Equal-Weight on Owens & Minor, Lowers Price Target to $14

AHCO

AdaptHealth Corp shares are trading lower after the company reported worse-than-expected Q3 sales and revised its FY24 net revenue guidance

Cleveland-Cliffs shares are trading lower following worse-than-expected Q3 financial results.

LSCC

Lattice Semiconductor shares are trading lower following soft Q4 guidance.

Mission Produce shares are trading higher after the company raised its Q4 guidance above estimates.

Barclays analyst Gena Wang maintains BioCryst Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCRX#NASDAQ">BCRX</a>) with a Equal-Weight and raises the price target from $7 to $8.

BCRX

Barclays Maintains Equal-Weight on BioCryst Pharma, Raises Price Target to $8

Barclays analyst Ryan Macwilliams maintains 8x8 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EGHT#NASDAQ">EGHT</a>) with a Equal-Weight and raises the price target from $2 to $2.5.

EGHT

Barclays Maintains Equal-Weight on 8x8, Raises Price Target to $2.5

SKYT

SkyWater Technologies shares are trading higher after Piper Sandler maintained an Overweight rating on the stock and raised its price target from $9 to $12.

Truist Financial analyst Neal Dingmann maintained a Buy rating on Ovintiv (OVV – Research Report) today. The company's shares closed last Friday at...

Truist Financial Remains a Buy on Ovintiv (OVV)

In a report released yesterday, Roger Read from Wells Fargo maintained a Hold rating on Ovintiv (OVV – Research Report), with a price target of $42...

Ovintiv (OVV) Receives a Hold from Wells Fargo

Ovintiv gains amid speculation on Coterra Energy approach

The 1-Minute Market Report October 6, 2024

An update from Ovintiv ( ($OVV) ) is now available. On October 9, 2024, Ovintiv Inc. shared a presentation with investors on its website, offering ...

Ovintiv Presents Corporate Performance Insights to Investors

In a report released on October 7, Gregory Pardy from RBC Capital maintained a Hold rating on Ovintiv (OVV – Research Report), with a price target ...

Ovintiv (OVV) Receives a Rating Update from a Top Analyst

Jefferies analyst Lloyd Byrne maintained a Buy rating on Ovintiv (OVV – Research Report) today and set a price target of $57.00. The company's shar...

Jefferies Sticks to Their Buy Rating for Ovintiv (OVV)

In a report released today, Betty Jiang from Barclays maintained a Buy rating on Ovintiv (OVV – Research Report), with a price target of $53.00. Th...

Barclays Sticks to Its Buy Rating for Ovintiv (OVV)

In a report released today, Devin McDermott from Morgan Stanley maintained a Hold rating on Ovintiv (OVV – Research Report), with a price target of...

Comments

Ovintiv

Vendite allo scoperto

Ovintiv (NYSE:OVV) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO